• About us
    • Who we are
    • Our strategy
    • How we are funded
    • Our people
    • Governance and structure
    • Reports and statements
    • Our impact
    • Suppliers
  • Our strategy
    • Our strategy
    • Neurodegeneration
    • Respiratory health
  • Working with us
    • Support for MRC researchers
    • Helping charities
    • Our partners
    • Available technologies
    • Advise & Connect: Covid-19
  • Funding
    • LifeArc Ventures
    • Rare disease research funding
    • Development Gap Fund
    • Current funding opportunities
  • Capabilities
    • Drug discovery
    • Antibody humanisation
    • IP management and technology transfer
    • Diagnostics development
  • Careers
    • Working at LifeArc
    • Our culture
    • Benefits and rewards
    • Students and fellows
    • How to apply
    • Job vacancies
  • News
    • Latest news
    • Case studies
    • Reports and publications
    • Newsletter

News

About
Our ventures team
Portfolio companies
News
Contact
News Releases 15 February 2023

LifeArc Ventures invests in Maxion Therapeutics

Investment in Maxion Therapeutics to drive antibody development for previously untreatable ion channel and GPCR-driven diseases

News Releases 15 November 2022

LifeArc Ventures invests in Surgery Hero, world’s first digital coaching clinic for patients

Seed funding will be used to scale the solution through the application of machine learning

Articles & blogs 20 October 2022

AbbVie acquires LifeArc portfolio company DJS Antibodies

AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS

News Releases 8 September 2022

LifeArc portfolio company Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics for up to $400 million

First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science

News Releases 17 May 2022

LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2

AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…

News Releases 2 December 2021

LifeArc participates in Series A funding round for company developing pioneering new gene therapies for neurodegenerative diseases

Helping to progress an innovative gene therapy platform from the bench to a stage where it is progressing closer to the clinic.

News Releases 16 November 2021

LifeArc unveils new strategy and £1.3 billion spend to drive life-changing science

Aims to transform the way diseases such as motor neurone disease are prevented, identified and treated.

News Releases 4 November 2021

10 new data-driven health companies selected for KQ Labs accelerator programme

10 innovative start-up companies working at the interface of biomedical and data science are to receive personalised…

News Releases 3 November 2021

LifeArc invests in company developing personalised drug and digital combination treatments

LifeArc and partners announce a £13 million financing deal in Closed Loop Medicine to enable the company to develop further and faster.

  • 1
  • 2
  • >
Quick links
  • Newsletter
  • Privacy policy
  • Cookie policy
  • Modern slavery statement
  • Sitemap
  • Contact us
Follow us
Get in touch
Lynton House
7-12 Tavistock Square
London WC1H 9LT UK

+44 (0)20 7391 2700
LifeArc is a charity registered with the Charity Commission for England and Wales no. 1015243 and a charity registered in Scotland with the Office of the Scottish Charity Regulator no. SC037861. LifeArc is a company limited by guarantee no. 2698321 incorporated in England and Wales. | © LifeArc 2023
Web design by TWK